Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse
Cancer Medicine · 2026
DOI: 10.1002/cam4.71936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Sayak Dey und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Malignant ovarian germ cell tumors [MOGCT] are rare cancers affecting young women and often present in advanced stages. This study aimed to evaluate their survival outcomes.
Methods
This is a retrospective study of patients diagnosed with MOGCT between 2013 to 2018. Clinicopathologic data were retrieved from electronic medical records. Survival analysis was done using the Kaplan – Meier method.
Results
A total of 170 patients were analyzed. The median age was 25 years (range: 15–68). Histological subtypes were dysgerminoma 37% (n‐63), yolk sac tumor 21% (n‐36), Immature teratoma 21% (n‐35), mixed germ cell tumor 17% (n‐29), and mature teratoma with somatic malignancy 4% (n‐7). Presentation in early stage (I and II) was 64% ( n = 108), while 36% ( n = 62) had advanced stage (Stage III/IV). Chemotherapy was received by 134 patients, of whom 49 received it in a neoadjuvant setting. Most patients ( n = 134–79%) underwent fertility‐sparing surgery, of whom 87% (117 of 134) resumed menstruation after completion of chemotherapy, with 18 successful pregnancies. Patients with relapsed yolk sac tumors (4) presented with ascites and peritoneal disease and could not be salvaged. Median follow‐up was 62 months [range 58–65 months]. The 5‐year progression‐free survival for stage I/II was 86% (95% CI 79–93) and for stage III/IV was 70% (95% CI 58–82). The 5‐year overall survival for stage I/II was 99% [95% CI 97–100] and for Stage III/IV was 88% (95% CI 79–97).
Conclusions
Patients presenting with advanced MOGCT can be offered fertility‐sparing surgery after neoadjuvant chemotherapy with no detriment in oncological outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
- Division of Gynecologic Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
- Department of Surgical Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
- Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
- Department of Pulmonary Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
- Department of Biochemistry, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
ORCID-Profile: Seema Gulia, Amita Maheshwari, Jaya Ghosh, Sudeep Gupta
Zitieren
APA
Dey, S., Anne, S., Rath, S., Nandhana, R., Gulia, S., Dash, B., Menon, S., Rekhi, B., Baheti, A., Sable, N., Popat, P., Tandon, S., Ghosh, K., Gurram, L., Parab, S. S., Logkumer, A. N., Jhadhav, S., Chopra, S., Surappa, S. T., …, & Gupta, S. (2026). Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse. Cancer Medicine. https://doi.org/10.1002/cam4.71936
Vancouver
Dey S, Anne S, Rath S, Nandhana R, Gulia S, Dash B, et al. Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse. Cancer Medicine. 2026. doi:10.1002/cam4.71936
BibTeX
@article{Dey2026,
author = {Dey, Sayak and Anne, Srikant and Rath, Sushmita and Nandhana, Ravindra and Gulia, Seema and Dash, Biswajit and Menon, Santosh and Rekhi, Bharat and Baheti, Akshay and Sable, Nilesh and Popat, Palak and Tandon, Sandeep and Ghosh, Kinjalka and Gurram, Lavanya and Parab, Sarika Shivram and Logkumer, Apenla N and Jhadhav, Sunita and Chopra, Supriya and Surappa, Shylasree T and Bansal, Vandana and Balsarkar, Geeta and Deodhar, Kedar and Maheshwari, Amita and Ghosh, Jaya and Gupta, Sudeep},
title = {Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71936}
}
EUVIMED